Advertisement

Head and Neck Pathology

, Volume 12, Issue 2, pp 261–268 | Cite as

Chordoma of the Head and Neck: A Review

  • Jason K. Wasserman
  • Denis Gravel
  • Bibianna Purgina
Invited Review

Abstract

Chordoma is a rare malignant bone tumor that can arise anywhere along the central neural axis and many involve head and neck sites, most commonly the skull base. The relative rarity of these tumors, combined with the complex anatomy of the head and neck, pose diagnostic challenges to pathologists. This article describes the pertinent clinical, pathologic, and molecular features of chordomas and describes how these features can be used to aid in formulating a differential diagnosis. Emphasis is placed on key diagnostic pitfalls and the importance of incorporating immunohistochemical information into the diagnosis.

Keywords

Chordoma Chondrosarcoma Skull base Brachyury Head and neck 

Notes

Compliance with Ethical Standards

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12:1–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer. 2013;119:2029–37.CrossRefPubMedGoogle Scholar
  3. 3.
    Mukherjee D, Chaichana KL, Gokaslan ZL, Aaronson O, Cheng JS, McGirt MJ. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine. 2011;14:143–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Lauer SR, Edgar MA, Gardner JM, Sebastian A, Weiss SW. Soft tissue chordomas: a clinicopathologic analysis of 11 cases. Am J Surg Pathol. 2013;37:719–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF, Flanagan AM. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Gladstone HB, Bailet JW, Rowland JP. Chordoma of the oropharynx: an unusual presentation and review of the literature. Otolaryngol Head Neck Surg. 1998;118:104–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Kataria SP, Batra A, Singh G, Kumar S, Sen R. Chordoma of skull base presenting as nasopharyngeal mass. J Neurosci Rural Pract. 2013;4:S95-97.Google Scholar
  8. 8.
    Khurram SA, Biswas D, Fernando M. A parapharyngeal soft tissue chordoma presenting with synchronous cervical lymph node metastasis: an unusual presentation. Head Neck Pathol. 2016;10:400–4.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lynn-Macrae A, Haines GK 3rd, Altman KW. Primary chordoma of the lateral nasal wall: case report and review. Ear Nose Throat J. 2005;84:593–5.PubMedGoogle Scholar
  10. 10.
    Nguyen RP, Salzman KL, Stambuk HE, Ahuja AT, Harnsberger HR. Extraosseous chordoma of the nasopharynx. AJNR Am J Neuroradiol. 2009;30:803–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Tao ZZ, Chen SM, Liu JF, Huang XL, Zhou L. Paranasal sinuses chordoma in pediatric patient: a case report and literature review. Int J Pediatr Otorhinolaryngol. 2005;69:1415–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. World Neurosurg. 2014;82:806–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee-Jones L, Aligianis I, Davies PA, Puga A, Farndon PA, Stemmer-Rachamimov A, Ramesh V, Sampson JR. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer. 2004;41:80–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Oakley GJ, Fuhrer K, Seethala RR. Brachyury. SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol. 2008;21:1461–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fletcher CDM. World Health Organization., International Agency for Research on Cancer. (2013) WHO classification of tumours of soft tissue and bone. IARC Press, Lyon.Google Scholar
  16. 16.
    Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer. 1973;32:410–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Rosenberg AE, Brown GA, Bhan AK, Lee JM. Chondroid chordoma–a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol. 1994;101:36–41.CrossRefPubMedGoogle Scholar
  18. 18.
    Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases. Am J Surg Pathol. 2006;30:811–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M, Puri A. Revisiting chordoma with brachyury, a “new age” marker: analysis of a validation study on 51 cases. Arch Pathol Lab Med. 2010;134:1181–7.PubMedGoogle Scholar
  20. 20.
    Miettinen M, Wang Z, Lasota J, Heery C, Schlom J, Palena C. Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas: an immunohistochemical study of 5229 cases. Am J Surg Pathol. 2015;39:1305–12.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sangoi AR, Karamchandani J, Lane B, Higgins JP, Rouse RV, Brooks JD, McKenney JK. Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases. Mod Pathol. 2011;24:425–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, Flanagan AM. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209:157–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Chavez JA, Nasir Ud D, Memon A, Perry A. Anaplastic chordoma with loss of INI1 and brachyury expression in a 2-year-old girl. Clin Neuropathol. 2014;33:418–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Hasselblatt M, Thomas C, Hovestadt V, Schrimpf D, Johann P, Bens S, Oyen F, Peetz-Dienhart S, Crede Y, Wefers A, Vogel H, Riemenschneider MJ, Antonelli M, Giangaspero F, Bernardo MC, Giannini C, Ud Din N, Perry A, Keyvani K, van Landeghem F, Sumerauer D, Hauser P, Capper D, Korshunov A, Jones DT, Pfister SM, Schneppenheim R, Siebert R, Fruhwald MC, Kool M. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol. 2016;132:149–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, Schneppenheim R, Hayden MG, Cherry AM, Gokden M, Edwards MS, Fisher PG, Vogel H. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120:745–53.CrossRefPubMedGoogle Scholar
  26. 26.
    Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M. Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer. 2007;110:2457–67.CrossRefPubMedGoogle Scholar
  27. 27.
    Pamir MN, Ozduman K. Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas. Eur J Radiol. 2006;58:461–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE, Liebsch NJ. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol. 1999;23:1370–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Folpe AL, Agoff SN, Willis J, Weiss SW. Parachordoma is immunohistochemically and cytogenetically distinct from axial chordoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 1999;23:1059–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Sangoi AR, Dulai MS, Beck AH, Brat DJ, Vogel H. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. Am J Surg Pathol. 2009;33:669–81.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fischer C, Scheipl S, Zopf A, Niklas N, Deutsch A, Jorgensen M, Lohberger B, Froehlich EV, Leithner A, Gabriel C, Liegl-Atzwanger B, Rinner B. Mutation analysis of nine chordoma specimens by targeted next-generation cancer panel sequencing. J Cancer. 2015;6:984–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Akhavan-Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H. Expression of PDGFR-alpha, EGFR and c-MET in spinal chordoma: a series of 52 patients. Anticancer Res. 2014;34:623–30.PubMedGoogle Scholar
  33. 33.
    Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, Zhang K, Yang H. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol. 2014;31:886.CrossRefPubMedGoogle Scholar
  34. 34.
    Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, Choy E, Mankin H, Duan Z. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther. 2009;8:2597–605.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang K, Chen H, Zhang B, Sun J, Lu J, Chen K, Yang H. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Int J Clin Exp Pathol. 2015;8:608–14.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Bayrak OF, Gulluoglu S, Aydemir E, Ture U, Acar H, Atalay B, Demir Z, Sevli S, Creighton CJ, Ittmann M, Sahin F, Ozen M. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol. 2013;115:143–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X, Liu Z. Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS ONE. 2013;8:e66676.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Zou MX, Huang W, Wang XB, Li J, Lv GH, Wang B, Deng YW. Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients. Eur Spine J. 2015;24:1738–46.CrossRefPubMedGoogle Scholar
  39. 39.
    Marucci G, Morandi L, Mazzatenta D, Frank G, Pasquini E, Foschini MP. MGMT promoter methylation status in clival chordoma. J Neurooncol. 2014;118:271–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM, Kelley MJ. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 2009;41:1176–8.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Pillay N, Plagnol V, Tarpey PS, Lobo SB, Presneau N, Szuhai K, Halai D, Berisha F, Cannon SR, Mead S, Kasperaviciute D, Palmen J, Talmud PJ, Kindblom LG, Amary MF, Tirabosco R, Flanagan AM. A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet. 2012;44:1185–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Bruderlein S, Moller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol. 2011;223:327–35.CrossRefPubMedGoogle Scholar
  43. 43.
    Brandal P, Bjerkehagen B, Danielsen H, Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet. 2005;160:15–21.CrossRefPubMedGoogle Scholar
  44. 44.
    Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, Deshpande V, Schwab J, Duan Z, Xavier RJ, Hornicek FJ, Iafrate AJ. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS ONE. 2011;6:e18846.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, Moller P. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer. 2001;32:203–11.CrossRefPubMedGoogle Scholar
  46. 46.
    Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–43.CrossRefPubMedGoogle Scholar
  47. 47.
    Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol. 2012;29:201–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ, Parsa AT. A systematic review of intracranial chondrosarcoma and survival. J Clin Neurosci. 2009;16:1547–51.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cho YH, Kim JH, Khang SK, Lee JK, Kim CJ. Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients. Neurosurg Rev. 2008;31:35–43 (discussion 43).CrossRefPubMedGoogle Scholar
  50. 50.
    Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg. 2011;115:1094–105.CrossRefPubMedGoogle Scholar
  51. 51.
    Martin JJ, Niranjan A, Kondziolka D, Flickinger JC, Lozanne KA, Lunsford LD. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg. 2007;107:758–64.CrossRefPubMedGoogle Scholar
  52. 52.
    Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S. Imatinib in advanced chordoma: A retrospective case series analysis. Eur J Cancer. 2015;51:2609–14.CrossRefPubMedGoogle Scholar
  53. 53.
    Launay SG, Chetaille B, Medina F, Perrot D, Nazarian S, Guiramand J, Moureau-Zabotto L, Bertucci F. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer. 2011;11:423.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Moller P, Bruderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239:320–34.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs. 2009;20:953–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30:914–20.CrossRefPubMedGoogle Scholar
  57. 57.
    Forsyth PA, Cascino TL, Shaw EG, Scheithauer BW, O’Fallon JR, Dozier JC, Piepgras DG. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg. 1993;78:741–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Tihan T, Parsa AT. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol. 2010;98:101–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Mitchell A, Scheithauer BW, Unni KK, Forsyth PJ, Wold LE, McGivney DJ. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer. 1993;72:2943–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Colli BO, Al-Mefty O. Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg Focus. 2001;10:E1.CrossRefPubMedGoogle Scholar
  61. 61.
    Gay E, Sekhar LN, Rubinstein E, Wright DC, Sen C, Janecka IP, Snyderman CH. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery. 1995;36:887–96 (discussion 896–887).CrossRefPubMedGoogle Scholar
  62. 62.
    Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Parsa AT. A comprehensive analysis of intracranial chordoma and survival: a systematic review. Br J Neurosurg. 2011;25:446–53.CrossRefPubMedGoogle Scholar
  63. 63.
    Romeo S, Hogendoorn PC. Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol. 2006;209:143–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Borba LA, Al-Mefty O, Mrak RE, Suen J. Cranial chordomas in children and adolescents. J Neurosurg. 1996;84:584–91.CrossRefPubMedGoogle Scholar
  65. 65.
    Coffin CM, Swanson PE, Wick MR, Dehner LP. Chordoma in childhood and adolescence. A clinicopathologic analysis of 12 cases. Arch Pathol Lab Med. 1993;117:927–33.PubMedGoogle Scholar
  66. 66.
    Kaneko Y, Sato Y, Iwaki T, Shin RW, Tateishi J, Fukui M. Chordoma in early childhood: a clinicopathological study. Neurosurgery. 1991;29:442–6.CrossRefPubMedGoogle Scholar
  67. 67.
    Matsumoto J, Towbin RB, Ball WS Jr. Cranial chordomas in infancy and childhood. A report of two cases and review of the literature. Pediatr Radiol. 1989;20:28–32.CrossRefPubMedGoogle Scholar
  68. 68.
    Yadav R, Sharma MC, Malgulwar PB, Pathak P, Sigamani E, Suri V, Sarkar C, Kumar A, Singh M, Sharma BS, Garg A, Bakhshi S, Faruq M. Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Neuro Oncol. 2014;16:372–81.CrossRefPubMedGoogle Scholar
  69. 69.
    Chambers PW, Schwinn CP. Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol. 1979;72:765–76.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Division of Anatomical Pathology, Department of Pathology and Laboratory Medicine, The Ottawa HospitalUniversity of OttawaOttawaCanada

Personalised recommendations